Ignite Creation Date:
2024-05-05 @ 10:17 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00000748
Status:
COMPLETED
Last Update Posted:
2021-11-04
First Post:
1999-11-02
Brief Title:
A Randomized Comparative Prospective Study of Daily Trimethoprim Sulfamethoxazole TMS and Thrice-Weekly TMS for Prophylaxis Against PCP in HIV-Infected Patients
Sponsor:
National Institute of Allergy and Infectious Diseases NIAID
Organization:
National Institute of Allergy and Infectious Diseases NIAID
Study Overview
Official Title:
A Randomized Comparative Prospective Study of Daily Trimethoprim Sulfamethoxazole TMS and Thrice-Weekly TMS for Prophylaxis Against PCP in HIV-Infected Patients
Status:
COMPLETED
Status Verified Date:
2021-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To compare the safety and efficacy of two dosage regimens daily and thrice-weekly of sulfamethoxazoletrimethoprim SMXTMP TMS in the prevention of Pneumocystis carinii pneumonia PCP in high-risk HIV-infected patients
Previous tests have shown that SMXTMP given daily is effective in preventing recurrence of PCP and may be effective in preventing PCP in patients who have never developed it Because SMXTMP can cause side effects this study will attempt to determine the safest and most effective dose of this combination
Previous tests have shown that SMXTMP given daily is effective in preventing recurrence of PCP and may be effective in preventing PCP in patients who have never developed it Because SMXTMP can cause side effects this study will attempt to determine the safest and most effective dose of this combination
Detailed Description:
Previous tests have shown that SMXTMP given daily is effective in preventing recurrence of PCP and may be effective in preventing PCP in patients who have never developed it Because SMXTMP can cause side effects this study will attempt to determine the safest and most effective dose of this combination
Patients receive SMXTMP orally on a daily or thrice-weekly basis Patients are clinically evaluated every 4 months Patients on daily SMXTMP who develop a drug-related toxicity may be switched to thrice-weekly SMXTMP Duration of follow-up is 12 months
Patients receive SMXTMP orally on a daily or thrice-weekly basis Patients are clinically evaluated every 4 months Patients on daily SMXTMP who develop a drug-related toxicity may be switched to thrice-weekly SMXTMP Duration of follow-up is 12 months
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 11558 | REGISTRY | DAIDS ES Registry Number | None |